Cizzle Biotechnology Holdings Plc specializes in developing an advanced immunoassay diagnostic test. This innovative tool aims to identify the CIZ1B biomarker, facilitating the early detection of lung cancer. The company, previously known as Cizzle Biotechnology Limited, officially changed its corporate identity to Cizzle Biotechnology Holdings Plc in May 2021. Its main operational base is situated in London, United Kingdom.
Subscribe to see CIZZLE BIOTECHNOLOGY HOLDINGS PLC’s full profile → the full roster, investors in every round, weekly hiring history and every corporate event
CIZZLE BIOTECHNOLOGY HOLDINGS PLC is a biotechnology company headquartered in London, United Kingdom, founded in 2007. It is publicly listed (CIZ) with a market capitalisation of $9.2M. Xcout tracks 10 named people at CIZZLE BIOTECHNOLOGY HOLDINGS PLC, including Allan Syms (Executive Chairman).
4 more named people on record for CIZZLE BIOTECHNOLOGY HOLDINGS PLC, with roles, board committees and tenure — see the full roster →
A few of CIZZLE BIOTECHNOLOGY HOLDINGS PLC's closest competitors — see the full list of competitors and alternatives →
IMU Biosciences is headquartered in London, United Kingdom, and operates in the biotechnology sector. The company develops data platforms and immunological profiling technologies supported by a growing scientific team.
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.
As a biotechnology enterprise, bioAffinity Technologies, Inc. is dedicated to pioneering both non-invasive diagnostic solutions and precision therapeutics for cancer. Its portfolio features CyPath lung, a specialized diagnostic test designed for the early identification of lung cancer. Beyond diagnostics, the firm actively explores targeted therapies intended to combat cancer at a cellular level. This San Antonio, Texas-based company commenced operations in 2014.
Predicine Holdings Ltd provides next-generation liquid biopsy platforms and molecular profiling services for cancer research and precision medicine. The company utilizes proprietary blood- and urine-based assays to analyze circulating tumor DNA and RNA, serving biopharmaceutical partners and clinical researchers in oncology drug development and clinical trials.
Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Genomic Classifiers for prostate cancer diagnosis; Decipher Bladder Genomic Classifier for bladder cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; and Percepta Nasal Swab Test for lung cancer diagnosis. It also provides the nCounter analysis system services. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
CellCarta operates as a global contract research organization (CRO) providing specialized laboratory testing and biomarker services to support drug development and precision medicine. The company offers a wide range of services including immunology, proteomics, genomics, histopathology, and companion diagnostic development for pharmaceutical and biotechnology clients.
Funding rounds, acquisitions, new executives, launches and expansions, each with a two-line summary and a link to the source. One short email a day, only when there is news.
Free: up to 5 companies, daily. Subscribers also follow whole sectors and saved filters (M&A in Israel, AI funding…), get instant alerts, in-app notifications and signed webhooks, and open the full profile behind every name. Subscribe →
Something wrong or missing about CIZZLE BIOTECHNOLOGY HOLDINGS PLC? Suggest a correction
Post the link and the card appears automatically — each network fetches the image itself.